Zacks Investment Research on MSN11d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite SuccessImmunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, ...
Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...
Clinical Trials Arena on MSN12d
Immunovant will not seek approval for MG therapy, despite hitting endpointsImmunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
However, Immunovant (NASDAQ:IMVT) said it would not seek regulatory approvals for the drug in MG or CIDP and would wait until ...
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
Similar to other recent studies, this Phase 2b study in CIDP begins with a non-placebo controlled run-in (Period 1), during which participants whose disease had worsened during standard of care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback